Fig 4. A pan class I HDAC inhibitor works synergistically with a pan LXR agonist on the expression of apoE but not ABCA1 or LXR.

Treatment of TO901317 (●), MS275 (▲) or co-treatment of the compounds (TO901317 + 100 nM MS275 (o) or MS275 + 20 nM TO901317 (Δ)) on the levels of secreted apoE protein (A), and the levels of apoE mRNA (B), ABCA1 mRNA (C), and LXRα mRNA (D) in CCF-STTG1 cells. For co-treatment, the amount of apoE protein and apoE, ABCA1, and LXRα mRNA levels were normalized to vehicle treated controls (Veh1) and the effect of the constant compound (100 nM MS275 or 20 nM TO901317, denoted Veh2) was subtracted out after normalization. The average of GAPDH and 18S mRNA were used as endogenous controls for normalization of mRNA levels. See S3 Table for gene expression assays. All data are represented as values ±SEM.